ArticleJournal of Crohn's & colitis2020

Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.

Frank I Scott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.